Navigation Links
Novogen and Marshall Edwards Sign Asset Purchase Agreement
Date:12/21/2010

SYDNEY and SAN DIEGO, Dec. 21, 2010 /PRNewswire-FirstCall/ -- Novogen Limited and Marshall Edwards, Inc. (Nasdaq: MSHL), an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism, announced today that they have entered into a definitive asset purchase agreement pursuant to which Marshall Edwards will acquire Novogen's isoflavone-based intellectual property portfolio in exchange for $4 million of convertible preferred stock.

"Over the past fifteen years, Novogen has conducted the largest and most comprehensive isoflavone-based research program in the world," said William D. Rueckert, Chairman of Novogen's Board of Directors. "We believe these assets are now better served in the hands of a company equipped with the drug development expertise and access to capital required to execute a clinical strategy and fully realize their value. Meanwhile, this transaction serves to bolster our ownership stake in Marshall Edwards, a significant value driver for our company going forward."

"This agreement represents the culmination of a watershed year at Marshall Edwards," said Professor Bryan Williams, Ph.D., Chairman of Marshall Edwards' Board of Directors. "Now armed with a hand-selected management team, world-class oncology drug development expertise and the flexibility to develop these valuable assets, we are poised to enter the clinic with two next-generation drug candidates in the coming year. In addition, this strategic acquisition will enable us to explore other potential candidates and indications within the portfolio while enhancing our ability to partner."

Utilizing a novel isoflavone-based technology platform, researchers at Novogen have generated more than 400 new chemical structures, including a number of compounds that have demonstrated robust anti-tumor activity in cancer cells. Previously, Marshall Edwards licen
'/>"/>

SOURCE Marshall Edwards, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Marshall Edwards CEO to Present at Lazard Capital Markets Healthcare Conference
2. Marshall Edwards CEO to Present at JMP Securities Healthcare Conference
3. Nobel Prize Winner Robert Edwards: A Personal Memoir by the Only American Physician to Participate in Developing IVF
4. Protege of Nobel Prize Winner Robert Edwards Carries on his IVF Legacy
5. Solutia Announces Sale of Perkalink® Business and Select Primary Accelerators Assets
6. Private Sector Investment in Agriculture Emerging as a Significant Alternative Asset Class: New HighQuest Partners Study
7. Genaera Liquidating Trust To Sell Remaining Proprietary Assets
8. OTCBB-WNDM Announces LOI to Acquire VHGI Assets for $10 Million Cash/Stock
9. Pharmasset to Webcast an Investor Event from the AASLD Meeting
10. Corgenix Secures $1,750,000 Asset Based Credit Facility Representing Initial Gross Proceeds of $1.109 Million
11. Gen-Probe to Consolidate Industrial Assets Into New, Independent Company
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... N.C. (PRWEB) May 01, 2015 ... Charlotte (UNC Charlotte) spin-out company, announced that Pinku Mukherjee, ... the UNC Board of Governors’ highest faculty honor. ... to humanity’s welfare , for her innovative research and ... Max Gardner Award represents a crowning moment in my ...
(Date:5/1/2015)... , May 1, 2015 A ... for antithrombotic drugs will reach $22.4bn in 2019. That ... World Industry and Market Prospects 2015-2025 , ... that investigation is to provide forecasts and qualitative analyses ... information publisher and consultancy in London, UK ...
(Date:5/1/2015)... SILVER SPRING, Md. and RESEARCH TRIANGLE ... Corporation (NASDAQ: UTHR ) announced today that Roger ... Therapeutics, will provide an overview and update on the company,s ... Care Conference in Boston, Massachusetts . ... 2015, at 3:30 PM Eastern Time, and can be accessed ...
(Date:4/30/2015)... 30, 2015 Cytokinetics, Incorporated (Nasdaq: CYTK) reported ... 2015 were $4.4 million, compared to $8.0 million during the ... first quarter was $8.9 million, or $0.23 per basic and ... the same period in 2014, of $8.7 million, or $0.27 ... 2015, cash, cash equivalents and investments totaled $117.5 million. ...
Breaking Biology Technology:OncoTAb CSO Awarded the University of North Carolina’s O. Max Gardner Award 2Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 2Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 3Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 4Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 5Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 2Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 3Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 4Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 5Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 6Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 7Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 8
... CGCP), announced that the company will release results,for ... to market open on,Wednesday, November 14, 2007. The ... Senior Vice President and Chief Financial Officer William ... day at 12:00 p.m. Eastern,time (9:00 a.m. Pacific ...
... Oct. 24 Cell Therapeutics,Inc. (CTI) (Nasdaq ... at,the 19th annual AACR-NCI-EORTC Symposium show its ... refractory to currently,marketed platinum agents carboplatin, cisplatin ... trials in late 2008. "Bis-platinates represent ...
... /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.,("Oncolytics") (TSX:ONC, NASDAQ:ONCY) ... of approval from the U.K. Medicines and ... Trial Application (CTA) to begin,a clinical trial ... cyclophosphamide, a chemotherapeutic agent as well as,immune ...
Cached Biology Technology:Cardiogenesis Corporation to Report Third Quarter 2007 Results on November 14th 2First New Class of Platinum-Based Chemotherapy Drug Candidates in 30 Years Demonstrate Ability to Kill Tumors Resistant to Currently Marketed Platinum Drugs 2First New Class of Platinum-Based Chemotherapy Drug Candidates in 30 Years Demonstrate Ability to Kill Tumors Resistant to Currently Marketed Platinum Drugs 3Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide 2Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide 3
(Date:4/1/2015)... , April 1, 2015   Medisafe ™, the ... users across iOS and Android ... integrating biofeedback into the platform to allow patients to ... For the first time, patients will be able to ... dose impacts important biometrics, such as glucose levels and ...
(Date:3/24/2015)... , Mar. 24, 2015 Research and Markets ... of the "Global Iris Recognition Market 2015-2019" ... the Global Iris Recognition market to grow at a ... This report covers the present scenario and the ... the period 2015-2019. To calculate the market size, the ...
(Date:3/23/2015)... , March 23, 2015   HOYOS Labs , ... company, today announced that the Company will demonstrate multiple ... enterprise and consumers at Connect:ID on March 23 through ... HOYOS Labs will highlight the IEEE Biometric Open Protocol ... ; and enterprise access control system. BOPS was invented ...
Breaking Biology News(10 mins):Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3
... of how plants "breathe" may help us breed and select ... of Toronto study. , The paper, which offers the first ... surface pores, appears in the July 12 issue of Current ... and senior author Malcolm Campbell. "This is a gene that ...
... intense selective logging stopped in the region now ... guenon (Cercophithecus ascanius) is a primate still in ... new study, changed the ecological balance for these ... door for multiple parasitic infections. , The researchers ...
... sneak past the blood brain barrier, which protects the brain ... particularly invasive brain cancer, according to a new Saint Louis ... Academy of Sciences Online Early Edition the week of Aug. ... drugs into the brain, you can cure brain cancer," says ...
Cached Biology News:Genetic discovery could lead to drought-resistant plants 2Logging changed ecological balance for monkeys, damaged health 2Logging changed ecological balance for monkeys, damaged health 3Slipping past the blood brain barrier: Research shows potential treatment for brain cancer 2
... CYCLES. This kit allows the quantitation of ... DNA affinity-mediated capture of free nucleosomes followed ... mono- and oligonucleosomes are captured on pre-coated ... antibody then binds to the histone component ...
OptiBuffer is a fully optimised medium, designed for,the electroporation of eukaryotic cells. OptiBuffer,improves both transfection efficiencies and survival,rates over PBS or other standard culture...
OmniSlide Heated Wash Module. 2 independent chambers with precise temperature control from ambient of 5C to 70C. Each chamber holds 1 slide rack (20 slides). Includes 2 x Wash Sleeves, 1 x Slide R...
HIV Reverse Transcriptase provides an excellent target for evaluating antiviral agents or catalyzing error prone synthesis on RNA and DNA templates....
Biology Products: